首页> 美国卫生研究院文献>other >SCORE Study Report 15: Incidence Risk Factors and Timing of Elevated Intraocular Pressure after Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion
【2h】

SCORE Study Report 15: Incidence Risk Factors and Timing of Elevated Intraocular Pressure after Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion

机译:SCORE研究报告15:玻璃体腔注射曲安奈德乙酰丙酮注射液治疗视网膜静脉阻塞引起的黄斑水肿后发生眼压升高的发生率危险因素和时间

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Importance:The >Standard of Care versus >COrticosteroid for >REtinal Vein Occlusion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema and improving visual acuity in participants with retinal vein occlusion. Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provide guidance for clinical decision-making and management of patients treated with IVTA.
机译:重要性:> RE 终末静脉阻塞(SCORE)的> S 护理标准与> CO 类固醇相比,玻璃体内丙酮酸曲安奈德(IVTA)有效减少视网膜静脉阻塞参与者的黄斑水肿和改善视力。对IVTA发生后的发生率,危险因素和眼内压(IOP)升高时间进行二次分析可为IVTA治疗患者的临床决策和管理提供指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号